China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026)
China Pharma Holdings (CPHI) posted Change in Account Payables of -$67771.0 for Q1 2026, down 123.19% on a QoQ basis from $292259.0 in Q4 2025, and down 120.99% year-over-year from $322935.0 in Q1 2025.
China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026) Analysis & Trends
China Pharma Holdings' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$67771.0 for Q1 2026.
- Quarterly Change in Account Payables fell 120.99% year-over-year to -$67771.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259603.0 (up 374.97% YoY) and the FY2025 annual result came in at $650309.0, up 188.61% from the prior year.
- Change in Account Payables was -$67771.0 for Q1 2026 at China Pharma Holdings, down from $292259.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $442807.0 in Q3 2023 and bottomed at -$505339.0 in Q2 2024.
- A 5-year average of -$1592.2 and a median of $54437.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 3045.77% — and 2024, when it sank 414.87%.
- China Pharma Holdings' Change in Account Payables stood at $238485.0 in 2022, then plunged by 54.75% to $107922.0 in 2023, then plunged by 244.32% to -$155753.0 in 2024, then soared by 287.64% to $292259.0 in 2025, then slumped by 123.19% to -$67771.0 in 2026.
- Business Quant data shows CPHI's Change in Account Payables at -$67771.0 in Q1 2026, $292259.0 in Q4 2025, and $54437.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -67,771.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67,771.00 |
| Mar 31, 2026 | -67,771.00 |
| Dec 31, 2025 | 292,259.00 |
| Dec 31, 2025 | 292,259.00 |
| Sep 30, 2025 | 54,437.00 |
| Sep 30, 2025 | 54,437.00 |
| Jun 30, 2025 | -19,322.00 |
| Jun 30, 2025 | -19,322.00 |
| Mar 31, 2025 | 322,935.00 |
| Mar 31, 2025 | 322,935.00 |
| Dec 31, 2024 | -155,753.00 |
| Dec 31, 2024 | -155,753.00 |
| Sep 30, 2024 | 243,744.00 |
| Sep 30, 2024 | 243,744.00 |
| Jun 30, 2024 | -505,339.00 |
| Jun 30, 2024 | -505,339.00 |
| Mar 31, 2024 | -316,568.00 |
| Mar 31, 2024 | -316,568.00 |
| Dec 31, 2023 | 107,922.00 |
| Dec 31, 2023 | 107,922.00 |